SPA
ANIK icon

Sherbrooke Park Advisers’s Anika Therapeutics ANIK Stock Holding History

Sherbrooke Park Advisers’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-13,681
Closed -$338K – 756
2024
Q3 		$338K Buy
+13,681
New +$355K 0.08% 516

Other funds holding ANIK

TI
Trigran Investments Northbrook, Illinois $545M AUM 56.2% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AFA
Alta Fundamental Advisers New York $333M AUM 102.25% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Boothbay Fund Management
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
CM
Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return

Sherbrooke Park Advisers's ANIK Position: Q4 2024 in Review

Sherbrooke Park Advisers sold out of Anika Therapeutics (ANIK) in Q4 2024, closing a stake of 13,681 shares — an estimated $338K sold.

Sherbrooke Park Advisers first reported a position in ANIK in Q3 2024 and held it in 1 quarter. The position peaked at $338K in Q3 2024. 109 funds tracked by Wall St. Rank hold ANIK as of Q4 2024.

  • Sherbrooke Park Advisers reported no remaining Anika Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 13,681 Anika Therapeutics shares in Q4 2024, an estimated $338K.
  • Sherbrooke Park Advisers first reported a position in Anika Therapeutics in Q3 2024 and held it in 1 quarter.
  • Sherbrooke Park Advisers's Anika Therapeutics position peaked at $338K in Q3 2024.
  • 109 funds tracked by Wall St. Rank held Anika Therapeutics as of Q4 2024.

Based on Sherbrooke Park Advisers's 13F filing for Q4 2024, filed 14 Feb 2025.